Loading…
The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)
Recently, we established new histopathological subtypes of high-grade serous ovarian cancer (HGSOC) that include the mesenchymal transition (MT) type, the immune reactive (IR) type, the solid and proliferative (SP) type and the papillo-glandular (PG) type. Furthermore, we identified that the mesench...
Saved in:
| Published in: | Gynecologic oncology 2019-05, Vol.153 (2), p.312-319 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c359t-25459993861252a2ebaf6250500245e61814a4768b63148ca1881651dee109a03 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c359t-25459993861252a2ebaf6250500245e61814a4768b63148ca1881651dee109a03 |
| container_end_page | 319 |
| container_issue | 2 |
| container_start_page | 312 |
| container_title | Gynecologic oncology |
| container_volume | 153 |
| creator | Murakami, Ryusuke Matsumura, Noriomi Michimae, Hirofumi Tanabe, Hiroshi Yunokawa, Mayu Iwase, Haruko Sasagawa, Motoi Nakamura, Toshiaki Tokuyama, Osamu Takano, Masashi Sugiyama, Toru Sawasaki, Takashi Isonishi, Seiji Takehara, Kazuhiro Nakai, Hidekatsu Okamoto, Aikou Mandai, Masaki Konishi, Ikuo |
| description | Recently, we established new histopathological subtypes of high-grade serous ovarian cancer (HGSOC) that include the mesenchymal transition (MT) type, the immune reactive (IR) type, the solid and proliferative (SP) type and the papillo-glandular (PG) type. Furthermore, we identified that the mesenchymal transcriptome subtype might be sensitive to taxane. We investigated whether these different histopathological subtypes of HGSOC require individualized chemotherapy for optimal treatment.
We conducted the Japanese Gynecologic Oncology Group (JGOG) 3016A1 study, wherein we collected hematoxylin and eosin slides (total n = 201) and performed a histopathological analysis of patients with HGSOC registered in the JGOG3016 study, which compared the efficacy of conventional paclitaxel and carboplatin (TC) and dose-dense TC (ddTC). We analyzed the differences in progression-free survival (PFS) and overall survival (OS) among the four histopathological subtypes. We then compared the PFS between the TC group and the ddTC group for each histopathological subtype.
There were significant differences in both PFS and OS among the four histopathological subtypes (p = 0.001 and p |
| doi_str_mv | 10.1016/j.ygyno.2019.02.010 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2190118307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825819301209</els_id><sourcerecordid>2190118307</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-25459993861252a2ebaf6250500245e61814a4768b63148ca1881651dee109a03</originalsourceid><addsrcrecordid>eNp9UsFuEzEQXRCIhsKFKxKaYzkkjL3x1luJQ1RBoKqUSzlbXu8k62rXXmwnsH-P0xSkXrjYHs2b92Y8ryjeM1wwZNWn-8W0m5xfcGT1AvkCGT4vZgxrMa-kqF8UM8Qa55ILeVa8jvEeEUtk_FVxVqIUZVmx2bN3dx3BQJGc6aZB95CCdtEm6x3EfZOmMad9IAgUR58zB4LkofWRoCWXz6R_a0dgOhp86ijocQLjh8Y6auGXTR0YHRo_9jpZB6nT7khgvDuQO8ocNU8U2rVPsE8oc9zZXQe7oFuCSMHvI_iDDjYT5ipjnR_0Faxy2-FAE_gt3Ogx8-Ye15Mj43u_swY27uE1wTpTjBDTvp3g4ma9WefPqVbs45vi5Vb3kd4-3ufFj69f7q6_zW836-_Xq9u5KUWd5lwsRV3XpawYF1xzavS24gIFIl8KqphkS728rGRTlWwpjWZSskqwlijvSGN5XlyceMfgf-4pJjXYaKjvc895OMVZjYzJEi8ztDxBTfAxBtqqMdhBh0kxVEczqHv1YAZ1NINCrrIZctWHR4F9M1D7r-bv9jPg8wlAecyDpaCisdkJ1NpAJqnW2_8K_AGAucu1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2190118307</pqid></control><display><type>article</type><title>The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)</title><source>ScienceDirect Journals</source><creator>Murakami, Ryusuke ; Matsumura, Noriomi ; Michimae, Hirofumi ; Tanabe, Hiroshi ; Yunokawa, Mayu ; Iwase, Haruko ; Sasagawa, Motoi ; Nakamura, Toshiaki ; Tokuyama, Osamu ; Takano, Masashi ; Sugiyama, Toru ; Sawasaki, Takashi ; Isonishi, Seiji ; Takehara, Kazuhiro ; Nakai, Hidekatsu ; Okamoto, Aikou ; Mandai, Masaki ; Konishi, Ikuo</creator><creatorcontrib>Murakami, Ryusuke ; Matsumura, Noriomi ; Michimae, Hirofumi ; Tanabe, Hiroshi ; Yunokawa, Mayu ; Iwase, Haruko ; Sasagawa, Motoi ; Nakamura, Toshiaki ; Tokuyama, Osamu ; Takano, Masashi ; Sugiyama, Toru ; Sawasaki, Takashi ; Isonishi, Seiji ; Takehara, Kazuhiro ; Nakai, Hidekatsu ; Okamoto, Aikou ; Mandai, Masaki ; Konishi, Ikuo</creatorcontrib><description>Recently, we established new histopathological subtypes of high-grade serous ovarian cancer (HGSOC) that include the mesenchymal transition (MT) type, the immune reactive (IR) type, the solid and proliferative (SP) type and the papillo-glandular (PG) type. Furthermore, we identified that the mesenchymal transcriptome subtype might be sensitive to taxane. We investigated whether these different histopathological subtypes of HGSOC require individualized chemotherapy for optimal treatment.
We conducted the Japanese Gynecologic Oncology Group (JGOG) 3016A1 study, wherein we collected hematoxylin and eosin slides (total n = 201) and performed a histopathological analysis of patients with HGSOC registered in the JGOG3016 study, which compared the efficacy of conventional paclitaxel and carboplatin (TC) and dose-dense TC (ddTC). We analyzed the differences in progression-free survival (PFS) and overall survival (OS) among the four histopathological subtypes. We then compared the PFS between the TC group and the ddTC group for each histopathological subtype.
There were significant differences in both PFS and OS among the four histopathological subtypes (p = 0.001 and p < 0.001, respectively). Overall, the MT subtype had the shortest PFS (median 1.4 y) and OS (median 3.6 y). In addition, the MT subtype had a longer PFS in the ddTC group (median 1.8 y) than in the TC group (median 1.2 y) (p = 0.01). Conversely, the other types had no significant difference in PFS when the two regimens were compared.
The MT type of HGSOC is sensitive to taxane; therefore, the ddTC regimen is recommended for this histopathological subtype.
•The morphologically defined mesenchymal transition type is highly representative of the mesenchymal transcriptome subtype.•The mesenchymal transition type has the worst prognosis and shows an increased rate of suboptimal surgery.•The mesenchymal transition type benefits from dose dense taxane and carboplatin chemotherapy compared to conventional TC.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2019.02.010</identifier><identifier>PMID: 30853361</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Dose dense TC ; High grade serous ovarian carcinoma ; Mesenchymal ; Ovarian cancer ; Taxane sensitivity</subject><ispartof>Gynecologic oncology, 2019-05, Vol.153 (2), p.312-319</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-25459993861252a2ebaf6250500245e61814a4768b63148ca1881651dee109a03</citedby><cites>FETCH-LOGICAL-c359t-25459993861252a2ebaf6250500245e61814a4768b63148ca1881651dee109a03</cites><orcidid>0000-0001-7354-6977 ; 0000-0003-4428-8029 ; 0000-0002-5079-0464</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30853361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murakami, Ryusuke</creatorcontrib><creatorcontrib>Matsumura, Noriomi</creatorcontrib><creatorcontrib>Michimae, Hirofumi</creatorcontrib><creatorcontrib>Tanabe, Hiroshi</creatorcontrib><creatorcontrib>Yunokawa, Mayu</creatorcontrib><creatorcontrib>Iwase, Haruko</creatorcontrib><creatorcontrib>Sasagawa, Motoi</creatorcontrib><creatorcontrib>Nakamura, Toshiaki</creatorcontrib><creatorcontrib>Tokuyama, Osamu</creatorcontrib><creatorcontrib>Takano, Masashi</creatorcontrib><creatorcontrib>Sugiyama, Toru</creatorcontrib><creatorcontrib>Sawasaki, Takashi</creatorcontrib><creatorcontrib>Isonishi, Seiji</creatorcontrib><creatorcontrib>Takehara, Kazuhiro</creatorcontrib><creatorcontrib>Nakai, Hidekatsu</creatorcontrib><creatorcontrib>Okamoto, Aikou</creatorcontrib><creatorcontrib>Mandai, Masaki</creatorcontrib><creatorcontrib>Konishi, Ikuo</creatorcontrib><title>The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Recently, we established new histopathological subtypes of high-grade serous ovarian cancer (HGSOC) that include the mesenchymal transition (MT) type, the immune reactive (IR) type, the solid and proliferative (SP) type and the papillo-glandular (PG) type. Furthermore, we identified that the mesenchymal transcriptome subtype might be sensitive to taxane. We investigated whether these different histopathological subtypes of HGSOC require individualized chemotherapy for optimal treatment.
We conducted the Japanese Gynecologic Oncology Group (JGOG) 3016A1 study, wherein we collected hematoxylin and eosin slides (total n = 201) and performed a histopathological analysis of patients with HGSOC registered in the JGOG3016 study, which compared the efficacy of conventional paclitaxel and carboplatin (TC) and dose-dense TC (ddTC). We analyzed the differences in progression-free survival (PFS) and overall survival (OS) among the four histopathological subtypes. We then compared the PFS between the TC group and the ddTC group for each histopathological subtype.
There were significant differences in both PFS and OS among the four histopathological subtypes (p = 0.001 and p < 0.001, respectively). Overall, the MT subtype had the shortest PFS (median 1.4 y) and OS (median 3.6 y). In addition, the MT subtype had a longer PFS in the ddTC group (median 1.8 y) than in the TC group (median 1.2 y) (p = 0.01). Conversely, the other types had no significant difference in PFS when the two regimens were compared.
The MT type of HGSOC is sensitive to taxane; therefore, the ddTC regimen is recommended for this histopathological subtype.
•The morphologically defined mesenchymal transition type is highly representative of the mesenchymal transcriptome subtype.•The mesenchymal transition type has the worst prognosis and shows an increased rate of suboptimal surgery.•The mesenchymal transition type benefits from dose dense taxane and carboplatin chemotherapy compared to conventional TC.</description><subject>Dose dense TC</subject><subject>High grade serous ovarian carcinoma</subject><subject>Mesenchymal</subject><subject>Ovarian cancer</subject><subject>Taxane sensitivity</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9UsFuEzEQXRCIhsKFKxKaYzkkjL3x1luJQ1RBoKqUSzlbXu8k62rXXmwnsH-P0xSkXrjYHs2b92Y8ryjeM1wwZNWn-8W0m5xfcGT1AvkCGT4vZgxrMa-kqF8UM8Qa55ILeVa8jvEeEUtk_FVxVqIUZVmx2bN3dx3BQJGc6aZB95CCdtEm6x3EfZOmMad9IAgUR58zB4LkofWRoCWXz6R_a0dgOhp86ijocQLjh8Y6auGXTR0YHRo_9jpZB6nT7khgvDuQO8ocNU8U2rVPsE8oc9zZXQe7oFuCSMHvI_iDDjYT5ipjnR_0Faxy2-FAE_gt3Ogx8-Ye15Mj43u_swY27uE1wTpTjBDTvp3g4ma9WefPqVbs45vi5Vb3kd4-3ufFj69f7q6_zW836-_Xq9u5KUWd5lwsRV3XpawYF1xzavS24gIFIl8KqphkS728rGRTlWwpjWZSskqwlijvSGN5XlyceMfgf-4pJjXYaKjvc895OMVZjYzJEi8ztDxBTfAxBtqqMdhBh0kxVEczqHv1YAZ1NINCrrIZctWHR4F9M1D7r-bv9jPg8wlAecyDpaCisdkJ1NpAJqnW2_8K_AGAucu1</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Murakami, Ryusuke</creator><creator>Matsumura, Noriomi</creator><creator>Michimae, Hirofumi</creator><creator>Tanabe, Hiroshi</creator><creator>Yunokawa, Mayu</creator><creator>Iwase, Haruko</creator><creator>Sasagawa, Motoi</creator><creator>Nakamura, Toshiaki</creator><creator>Tokuyama, Osamu</creator><creator>Takano, Masashi</creator><creator>Sugiyama, Toru</creator><creator>Sawasaki, Takashi</creator><creator>Isonishi, Seiji</creator><creator>Takehara, Kazuhiro</creator><creator>Nakai, Hidekatsu</creator><creator>Okamoto, Aikou</creator><creator>Mandai, Masaki</creator><creator>Konishi, Ikuo</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7354-6977</orcidid><orcidid>https://orcid.org/0000-0003-4428-8029</orcidid><orcidid>https://orcid.org/0000-0002-5079-0464</orcidid></search><sort><creationdate>20190501</creationdate><title>The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)</title><author>Murakami, Ryusuke ; Matsumura, Noriomi ; Michimae, Hirofumi ; Tanabe, Hiroshi ; Yunokawa, Mayu ; Iwase, Haruko ; Sasagawa, Motoi ; Nakamura, Toshiaki ; Tokuyama, Osamu ; Takano, Masashi ; Sugiyama, Toru ; Sawasaki, Takashi ; Isonishi, Seiji ; Takehara, Kazuhiro ; Nakai, Hidekatsu ; Okamoto, Aikou ; Mandai, Masaki ; Konishi, Ikuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-25459993861252a2ebaf6250500245e61814a4768b63148ca1881651dee109a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Dose dense TC</topic><topic>High grade serous ovarian carcinoma</topic><topic>Mesenchymal</topic><topic>Ovarian cancer</topic><topic>Taxane sensitivity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murakami, Ryusuke</creatorcontrib><creatorcontrib>Matsumura, Noriomi</creatorcontrib><creatorcontrib>Michimae, Hirofumi</creatorcontrib><creatorcontrib>Tanabe, Hiroshi</creatorcontrib><creatorcontrib>Yunokawa, Mayu</creatorcontrib><creatorcontrib>Iwase, Haruko</creatorcontrib><creatorcontrib>Sasagawa, Motoi</creatorcontrib><creatorcontrib>Nakamura, Toshiaki</creatorcontrib><creatorcontrib>Tokuyama, Osamu</creatorcontrib><creatorcontrib>Takano, Masashi</creatorcontrib><creatorcontrib>Sugiyama, Toru</creatorcontrib><creatorcontrib>Sawasaki, Takashi</creatorcontrib><creatorcontrib>Isonishi, Seiji</creatorcontrib><creatorcontrib>Takehara, Kazuhiro</creatorcontrib><creatorcontrib>Nakai, Hidekatsu</creatorcontrib><creatorcontrib>Okamoto, Aikou</creatorcontrib><creatorcontrib>Mandai, Masaki</creatorcontrib><creatorcontrib>Konishi, Ikuo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murakami, Ryusuke</au><au>Matsumura, Noriomi</au><au>Michimae, Hirofumi</au><au>Tanabe, Hiroshi</au><au>Yunokawa, Mayu</au><au>Iwase, Haruko</au><au>Sasagawa, Motoi</au><au>Nakamura, Toshiaki</au><au>Tokuyama, Osamu</au><au>Takano, Masashi</au><au>Sugiyama, Toru</au><au>Sawasaki, Takashi</au><au>Isonishi, Seiji</au><au>Takehara, Kazuhiro</au><au>Nakai, Hidekatsu</au><au>Okamoto, Aikou</au><au>Mandai, Masaki</au><au>Konishi, Ikuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>153</volume><issue>2</issue><spage>312</spage><epage>319</epage><pages>312-319</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Recently, we established new histopathological subtypes of high-grade serous ovarian cancer (HGSOC) that include the mesenchymal transition (MT) type, the immune reactive (IR) type, the solid and proliferative (SP) type and the papillo-glandular (PG) type. Furthermore, we identified that the mesenchymal transcriptome subtype might be sensitive to taxane. We investigated whether these different histopathological subtypes of HGSOC require individualized chemotherapy for optimal treatment.
We conducted the Japanese Gynecologic Oncology Group (JGOG) 3016A1 study, wherein we collected hematoxylin and eosin slides (total n = 201) and performed a histopathological analysis of patients with HGSOC registered in the JGOG3016 study, which compared the efficacy of conventional paclitaxel and carboplatin (TC) and dose-dense TC (ddTC). We analyzed the differences in progression-free survival (PFS) and overall survival (OS) among the four histopathological subtypes. We then compared the PFS between the TC group and the ddTC group for each histopathological subtype.
There were significant differences in both PFS and OS among the four histopathological subtypes (p = 0.001 and p < 0.001, respectively). Overall, the MT subtype had the shortest PFS (median 1.4 y) and OS (median 3.6 y). In addition, the MT subtype had a longer PFS in the ddTC group (median 1.8 y) than in the TC group (median 1.2 y) (p = 0.01). Conversely, the other types had no significant difference in PFS when the two regimens were compared.
The MT type of HGSOC is sensitive to taxane; therefore, the ddTC regimen is recommended for this histopathological subtype.
•The morphologically defined mesenchymal transition type is highly representative of the mesenchymal transcriptome subtype.•The mesenchymal transition type has the worst prognosis and shows an increased rate of suboptimal surgery.•The mesenchymal transition type benefits from dose dense taxane and carboplatin chemotherapy compared to conventional TC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30853361</pmid><doi>10.1016/j.ygyno.2019.02.010</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-7354-6977</orcidid><orcidid>https://orcid.org/0000-0003-4428-8029</orcidid><orcidid>https://orcid.org/0000-0002-5079-0464</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 2019-05, Vol.153 (2), p.312-319 |
| issn | 0090-8258 1095-6859 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2190118307 |
| source | ScienceDirect Journals |
| subjects | Dose dense TC High grade serous ovarian carcinoma Mesenchymal Ovarian cancer Taxane sensitivity |
| title | The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1) |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A00%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20mesenchymal%20transition%20subtype%20more%20responsive%20to%20dose%20dense%20taxane%20chemotherapy%20combined%20with%20carboplatin%20than%20to%20conventional%20taxane%20and%20carboplatin%20chemotherapy%20in%20high%20grade%20serous%20ovarian%20carcinoma:%20A%20survey%20of%20Japanese%20Gynecologic%20Oncology%20Group%20study%20(JGOG3016A1)&rft.jtitle=Gynecologic%20oncology&rft.au=Murakami,%20Ryusuke&rft.date=2019-05-01&rft.volume=153&rft.issue=2&rft.spage=312&rft.epage=319&rft.pages=312-319&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2019.02.010&rft_dat=%3Cproquest_cross%3E2190118307%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c359t-25459993861252a2ebaf6250500245e61814a4768b63148ca1881651dee109a03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2190118307&rft_id=info:pmid/30853361&rfr_iscdi=true |